Generate Biomedicines (NASDAQ:GENB) Releases Earnings Results, Misses Expectations By $0.59 EPS

Generate Biomedicines (NASDAQ:GENB) posted its quarterly earnings results on Thursday. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.59), Zacks reports.

Generate Biomedicines Trading Up 0.5%

Shares of NASDAQ GENB traded up $0.07 during trading on Friday, reaching $13.66. 291,612 shares of the stock were exchanged, compared to its average volume of 465,861. The business’s 50-day moving average price is $12.62. Generate Biomedicines has a twelve month low of $11.00 and a twelve month high of $15.89.

Analyst Upgrades and Downgrades

Several research firms have issued reports on GENB. Guggenheim began coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They set a “buy” rating and a $30.00 price objective for the company. The Goldman Sachs Group began coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They issued a “buy” rating and a $26.00 target price on the stock. HC Wainwright upped their price target on shares of Generate Biomedicines from $16.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday. Zacks Research upgraded Generate Biomedicines to a “hold” rating in a report on Wednesday, March 25th. Finally, Wall Street Zen cut Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Generate Biomedicines presently has an average rating of “Moderate Buy” and a consensus target price of $25.00.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.